Breast cancer p53 mutant is more likely to recur. p53 is a kind of oncogene, which can inhibit the proliferation of cancer cells, and it is the gene most likely to be mutated in breast cancer. Breast cancer p53 mutant indicates that the ability of p53 to inhibit the growth of cancer cells has disappeared, and the proliferation of cancer cells is not inhibited, so p53 gene mutation often indicates that the tumor has a poor prognosis. Breast cancer p53 mutant cancer cells are highly malignant, poorly differentiated, and very prone to peripheral tissue invasion and lymph node metastasis. However, in order to evaluate the prognosis of the patient, the patient should also be tested for estrogen and progesterone receptor positivity, and based on the results of various phenotypic tests, the recurrence of the tumor should be comprehensively evaluated. Breast cancer p53 mutant should adopt individualized comprehensive treatment plan, including drug treatment (adjuvant chemotherapy and neoadjuvant chemotherapy, etc.), surgical treatment (radical mastectomy, modified radical mastectomy, etc.), endocrine therapy (anti-estrogen therapy, aromatase inhibitor, etc.), targeted therapy (trastuzumab, lapatinib, etc.). The prognosis for patients with p53 mutant breast cancer is often poor, so patients should also undergo regular review and follow-up after regular treatment in the hospital, and should consult the doctor promptly if there is any sign of recurrence.